Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Deborah Donnell et al.|New England Journal of Medicine|2021Cited by 847
Defining success with HIV pre-exposure prophylaxisJessica E. Haberer, Kevin O’Reilly, David R. Bangsberg et al.|AIDS|2015Cited by 317
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSMSybil Hosek, Bret J. Rudy, Raphael J. Landovitz et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2016Cited by 278
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United StatesSybil Hosek, Craig M. Wilson, Raphael J. Landovitz et al.|JAMA Pediatrics|2017Cited by 226
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Beatriz Grinsztejn et al.|The Journal of Infectious Diseases|2021Cited by 129